Publications
Detailed Information
An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heo, J-H | - |
dc.contributor.author | Lee, S-T | - |
dc.contributor.author | Chu, K | - |
dc.contributor.author | Oh, M J | - |
dc.contributor.author | Park, H-J | - |
dc.contributor.author | Shim, J-Y | - |
dc.contributor.author | Kim, M | - |
dc.date.accessioned | 2010-07-07T01:19:33Z | - |
dc.date.available | 2010-07-07T01:19:33Z | - |
dc.date.issued | 2008-08-08 | - |
dc.identifier.citation | Eur J Neurol. 2008; 15(8): 865-868 | en |
dc.identifier.issn | 1468-1331 (Electronic) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18684311 | - |
dc.identifier.uri | https://hdl.handle.net/10371/68386 | - |
dc.description.abstract | BACKGROUND AND PURPOSE: Ginseng is one of the most popular herbs worldwide. Ginseng has various medical applications, and it seems to have significant effects as a cognition-enhancing drug. In this study, we examined the efficacy of Korean red ginseng (KRG) as an adjuvant therapy to conventional anti-dementia medications in patients with Alzheimer's disease. METHODS: The trial was designed as a 12-week randomized study. Sixty-one patients (24 males and 37 females) with Alzheimer's disease were randomly assigned to one of the following treatment groups: low-dose KRG (4.5 g/day, n = 15), high-dose KRG (9 g/day, n = 15) or control (n = 31). The Alzheimer's Disease Assessment Scale (ADAS), Korean version of the Mini-Mental Status Examination (K-MMSE) and Clinical Dementia Rating (CDR) scale were used to assess the change in cognitive and functional performance at the end of the 12-week study period. RESULTS: The patients in the high-dose KRG group showed significant improvement on the ADAS and CDR after 12 weeks of KRG therapy when compared with those in the control group (P = 0.032 and 0.006 respectively). The KRG treatment groups showed improvement from baseline MMSE when compared with the control group (1.42 vs. -0.48), but this improvement was not statistically significant. CONCLUSIONS: KRG showed good efficacy for the treatment of Alzheimer's disease; however, further studies with larger samples of patients and a longer efficacy trial should be conducted to confirm the efficacy of KRG. | en |
dc.description.sponsorship | This work was supported by grants from the Korean
Society of Ginseng. | en |
dc.language.iso | en | en |
dc.publisher | Wiley-Blackwell | en |
dc.subject | Aged | en |
dc.subject | Alzheimer Disease/complications/*drug therapy | en |
dc.subject | Cognition Disorders/*drug therapy/etiology | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Neuropsychological Tests | en |
dc.subject | Pilot Projects | en |
dc.subject | Panax | - |
dc.subject | Phytotherapy | - |
dc.title | An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease | en |
dc.type | Article | en |
dc.identifier.doi | 10.1111/j.1468-1331.2008.02157.x | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.